Bausch Health Companies Inc. (NASDAQ:BHC) | WebDisclosure

Switch to English

8306	Sociétés
115305	Mots-clés
55588	Articles
62608	Communiqués

Accueil
Sociétés
Bausch Health Companies Inc.

BRÈVE

publiée le 15/05/2024 à 14:05, il y a 6 mois 7 jours

Bausch Health Announces 2024 Annual Meeting of Shareholder Results

Corporate Governance Bausch Health Shareholder Meeting Executive Compensation Omnibus Incentive Plan
BRÈVE

publiée le 15/05/2024 à 14:05, il y a 6 mois 7 jours

Bausch Health annonce les résultats de l’assemblée annuelle des actionnaires 2024

Assemblée Générale Gouvernance D'Entreprise Bausch Santé Rémunération Des Dirigeants Plan Incitatif Omnibus
COMMUNIQUÉ DE PRESSE

publié le 15/05/2024 à 14:00, il y a 6 mois 7 jours

Bausch Health Announces 2024 Annual Meeting of Shareholder Results
Bausch Health Companies Inc. announces results of 2024 annual meeting of shareholders, including election of directors and approval of executive compensation

Shareholders Bausch Health Companies Inc. Annual Meeting Directors Executive Compensation
BRÈVE

publiée le 14/05/2024 à 22:26, il y a 6 mois 7 jours

Bausch Health annonce des mises à jour sur le litige Norwich XIFAXAN et une nouvelle soumission à la FDA

XIFAXAN Bausch Santé Contentieux Des Brevets Norwich Pharmaceutique Soumission À La FDA
BRÈVE

publiée le 14/05/2024 à 22:26, il y a 6 mois 7 jours

Bausch Health Announces Updates on Norwich XIFAXAN Litigation and New FDA Submission

XIFAXAN Bausch Health Patent Litigation FDA Submission Norwich Pharmaceuticals
COMMUNIQUÉ DE PRESSE

publié le 14/05/2024 à 22:21, il y a 6 mois 7 jours

Bausch Health Announces Updates Related to Norwich XIFAXAN Matters
Bausch Health and Salix Pharmaceuticals provide updates on litigation with Norwich Pharmaceuticals and potential generic version of XIFAXAN. Bausch Health to enforce intellectual property rights. Details on FDA approval process and patent infringement lawsuit

Salix Pharmaceuticals XIFAXAN Bausch Health Norwich Pharmaceuticals Intellectual Property Rights
BRÈVE

publiée le 09/05/2024 à 14:05, il y a 6 mois 13 jours

Salix Pharmaceuticals Appoints Bellamy Young as Spokesperson for Xifaxan Campaign

Salix Pharmaceuticals XIFAXAN FDA Approval Bellamy Young Overt Hepatic Encephalopathy
BRÈVE

publiée le 09/05/2024 à 14:05, il y a 6 mois 13 jours

Salix Pharmaceuticals nomme Bellamy Young porte-parole de la campagne Xifaxan

XIFAXAN Salix Pharmaceutique Approbation De La FDA Bellamy Jeune Encéphalopathie Hépatique Manifeste
COMMUNIQUÉ DE PRESSE

publié le 09/05/2024 à 14:00, il y a 6 mois 13 jours

Salix Pharmaceuticals announces Bellamy Young as Spokesperson for Xifaxan(R) (rifaximin)
Bausch Health and Salix Pharmaceuticals announce Bellamy Young as Xifaxan brand ambassador to raise awareness on OHE recurrence risk reduction. Campaign aims to educate about complications of cirrhosis

Salix Pharmaceuticals XIFAXAN Bausch Health Bellamy Young OHE Recurrence
BRÈVE

publiée le 02/05/2024 à 13:05, il y a 6 mois 20 jours

Bausch Health Announces First Quarter 2024 Results

Financial Results Adjusted EBITDA Pharmaceutical Industry Revenue Growth Bausch Health

Les Echos

Publié le 22/11/2024 à 14:35, il y a 1 heure 31 minutes

Communiqué de presse Thales
Publié le 22/11/2024 à 14:35, il y a 1 heure 31 minutes

Thales Press release
Publié le 21/11/2024 à 06:58, il y a 1 jour 9 heures

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 1 jour 9 heures

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 1 jour 9 heures

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 22/11/2024 à 15:55, il y a 11 minutes

Independent Proxy Advisory Firm ISS Recommends Signal Gold Shareholders Vote for Arrangement Resolution and Private Placement Resolution
Publié le 22/11/2024 à 15:15, il y a 51 minutes

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Publié le 22/11/2024 à 14:45, il y a 1 heure 21 minutes

Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs
Publié le 22/11/2024 à 14:30, il y a 1 heure 36 minutes

Allied Universal Named Presenting Sponsor of 2024 Lott IMPACT Trophy Recognizing College Football's Defensive Best
Publié le 22/11/2024 à 14:20, il y a 1 heure 46 minutes

Plaintree Systems Inc. Announces Second Quarter Fiscal 2025 Results

Voir tout ACCESSWIRE

EQS Group

Publié le 22/11/2024 à 15:27, il y a 39 minutes

EQS-Adhoc: Eckert & Ziegler raises its forecast for the current financial year once again
Publié le 22/11/2024 à 14:46, il y a 1 heure 19 minutes

Form 8.3 - The Vanguard Group, Inc.: International Paper Company
Publié le 22/11/2024 à 14:45, il y a 1 heure 20 minutes

Form 8.3 - The Vanguard Group, Inc.: Centamin plc
Publié le 22/11/2024 à 14:44, il y a 1 heure 21 minutes

Form 8.3 - The Vanguard Group, Inc.: AngloGold Ashanti plc
Publié le 22/11/2024 à 14:43, il y a 1 heure 22 minutes

Form 8.3 - The Vanguard Group, Inc.: International Distribution Services plc